Introduction {#s1}
============

Primary percutaneous coronary intervention (p-PCI) has become the treatment of choice for patients presenting with ST-segment elevation myocardial infarction (STEMI) when it can be performed expeditiously by an experienced team.^[@EHQ410C1]--[@EHQ410C6]^ The goal is restoration of flow within 90 min of presentation to a PCI-equipped centre or within 120 min from the time of the first medical contact.^[@EHQ410C7],[@EHQ410C8]^ This strategy has been found to be superior to thrombolytic therapy in improving morbidity and mortality. An important piece of information gained at the time of angiography and p-PCI is information not only about the culprit lesion but also about the extent and severity of the underlying coronary artery disease. In patients presenting with STEMI, multi-vessel coronary artery disease is found to be present from 41 to 67% of patients depending upon the baseline characteristics (especially age) of the specific population studied;^[@EHQ410C9]--[@EHQ410C12]^ however, in one study only 10% of STEMI patients initially treated by p-PCI had a clinical indication for non-culprit PCI during the subsequent follow-up of up to 3 years.^[@EHQ410C13]^ The presence of multi-vessel disease has been found to be associated with worse prognosis in patients with STEMI.^[@EHQ410C14]^ Identification of optimal strategies for treating these patients is the subject of considerable interest and controversy.

Treatment strategies vary widely from an aggressive approach which treats all significant lesions in the acute phase of p-PCI to a conservative approach with p-PCI of only the infarct-related artery (IRA) and subsequent medical therapy unless recurrent ischaemia occurs. Between these two extremes are other alternatives; mainly that of staged procedures with the IRA treated acutely and other lesions treated later during the hospital stay or within the first month following discharge. There is no randomized data to definitely answer the issues about the specific scientific merits of any of these approaches. However, there are increasing data from observational series. Each approach has advantages and disadvantages. This review paper summarizes the international experience and authors' opinion on this clinically important question. The authors have not tried to do a formal 'meta-analysis' and rather preferred to describe the current knowledge and to offer their view on the subject.

Aggressive approach: acute multi-vessel percutaneous coronary intervention during ST-segment elevation myocardial infarction {#s2}
============================================================================================================================

The potential advantages of the aggressive approach are completeness of revascularization, treatment of any secondary potentially unstable lesions, and possible shortening of cumulative hospital stay. The main disadvantages are increased contrast load (and thus increased risk of contrast-induced nephropathy), haemodynamic instability in the acute setting, and potentially disastrous complications of non-infarct artery PCI (*Table [1](#EHQ410TB1){ref-type="table"}*). Several studies reported promising results with multi-vessel PCI strategy. One group^[@EHQ410C15]^ reported a decrease in recurrent infarctions or ischaemia, but no survival benefit. Rigattieri *et al*.^[@EHQ410C16]^ found that p-PCI of the culprit vessel alone with subsequent medical treatment has better *early* outcomes, whereas multi-vessel-staged PCI tended to better *long-term* outcomes. Another Italian study^[@EHQ410C17]^ compared three different revascularization strategies in 214 consecutive patients with STEMI and multi-vessel coronary artery disease undergoing primary angioplasty: culprit vessel angioplasty-only (COR group); staged revascularization (SR group), and simultaneous treatment of non-IRA (CR group). During a mean follow-up of 2.5 years, at least one major adverse cardiac event occurred in 50% patients of the COR group, 20% of the SR group, and 23% of the CR group (*P* \< 0.001). Table 1Acute multi-vessel percutaneous coronary intervention during ST-segment elevation myocardial infarctionAdvantagesDisadvantagesComplete revascularizationIncreased contrast load/risk of contrast-induced nephropathyTreat ischaemia at a distanceRadiation exposureTreat secondary unstable lesions (plaque instability may not be limited to the culprit lesion)Complications of treating additional lesions may be potentially fatalPatient preference/comfortHaemodynamic and general clinical instability treating additional lesionsIncreased risk of stent thrombosis in patients with clopidogrel resistance/intolerance.Prothrombotic and inflammatory milieu in the acute phase of STEMICoronary spasm may lead to possible overestimation of stenosis severity in non-infarct arteries

Another single-centre registry^[@EHQ410C18]^ found among 745 p-PCI patients multi-vessel PCI in STEMI to be feasible and safe. This registry realistically described the relative proportions of single- (46%) vs. multi-vessel (54%) disease and the three most frequently used strategies for multi-vessel disease: p-PCI of the IRA only (39%), staged PCI (24%), and acute multi-vessel (37%) PCI (*Figure [1](#EHQ410F1){ref-type="fig"}*). Figure 1The relative proportion of single- vs. multi-vessel disease and of the three most frequently used PCI (percutaneous coronary intervention) strategies for multi-vessel disease (adopted from Corpus *et al*.^[@EHQ410C21]^).

Kong *et al*.^[@EHQ410C19]^ analysed patients undergoing PCI for STEMI in 2000--01 (multi-vessel angioplasty, *n* = 632 and infarct-related vessel angioplasty, *n* = 1350) from the New York State Angioplasty Registry database. The highest risk patients (previous myocardial infarction, angioplasty, bypass surgery, or cardiogenic shock) were excluded. In-hospital mortality was lower (0.8 vs. 2.3%, *P* = 0.018) in the multi-vessel angioplasty group. No differences were observed in other ischaemic complications, renal failure, or length of stay. After multivariate analysis, multi-vessel angioplasty remained a significant predictor of lower in-hospital death \[odds ratio (OR) = 0.27, 95% confidence interval (CI) = 0.08--0.90, *P* = 0.03\]. However, 0.8% in-hospital mortality for STEMI is not realistic and clearly shows, that this retrospective non-randomized study analysed highly selected, low-risk patients, and thus results cannot be applied to the routine clinical practice.

Chen *et al*.^[@EHQ410C20]^ evaluated the outcomes of multi-vessel PCI early after STEMI. Clinical outcomes were compared between patients who underwent multi-vessel PCI (*n* = 239) and patients who underwent treatment of the IRA alone (*n* = 1145). The primary endpoint was cumulative survival at 6, 12, and 36 months. Secondary endpoints included a composite of mortality, recurrent infarction, coronary artery bypass graft, or target vessel revascularization at the same time points. The multi-vessel PCI group had a significantly higher prevalence of adverse prognostic indicators. Despite this, observed event rates were similar between the multi-vessel PCI and single-vessel PCI groups. The Kaplan--Meier estimated 1-year survival was 0.91 (95% CI 0.87--0.95) for the multi-vessel PCI group and 0.93 (95% CI 0.92--0.95) for the single-vessel PCI group (*P* = 0.43). Similarly, 1-year survival free of recurrent infarction and target vessel revascularization rates were similar between the two groups: multi-vessel PCI 0.78 (95% CI 0.73--0.84) and single-vessel PCI 0.78 (95% CI 0.75--0.81).

Conservative approach: acute percutaneous coronary intervention of the infarct-related artery alone (followed by medical therapy unless recurrent ischaemia occurs) {#s3}
===================================================================================================================================================================

Other studies reported better outcomes with a more conservative strategy of p-PCI only on the IRA in the acute phase (*Table [2](#EHQ410TB2){ref-type="table"}*). The study of Corpus *et al*.^[@EHQ410C21]^ described significantly higher risk of re-infarction (13.0 vs. 2.8%, *P* \< .001) and even of repeat revascularization (25 vs. 15%, *P* = 0,007) among 506 patients when treated by multi-vessel PCI (152 patients) when compared with IRA-only PCI (354 patients). Table 2Infarct-related artery culprit lesions alone then monitor for ischaemiaAdvantagesDisadvantagesTreat only culprit lesionMay leave behind significant ischaemia-producing lesionsAvoid complications associated with treating other lesionsMay not treat other less severe unstable lesionsThe indication for non-infarct artery PCI can be supported by the objective evidence for myocardial ischaemia in regions supplied by this non-infarct arteryMay not prevent recurrent ischaemiaThe ability to discuss with patients and their families the relative risks and benefits of treating the non-infarct related lesion vs. continued medical therapy or surgical optionsPatients have to return to laboratory routinely

The New York State PCI Registry^[@EHQ410C22]^ reported that in haemodynamically stable patients with multi-vessel disease, acute phase multi-vessel PCI results in an increased in-hospital mortality (2.4%) when compared with IRA-only PCI (0.9%, *P* = 0,04). On the contrary, patients undergoing staged multi-vessel PCI within 60 days after the index procedure had a significantly lower 12-month mortality rate than patients undergoing culprit vessel PCI only (1.3 vs. 3.3%, *P* = 0.04).

Khattab *et al*.^[@EHQ410C23]^ found no mortality benefit from acute multi-vessel PCI. Roe *et al*.^[@EHQ410C24]^ described even increased mortality with acute multi-vessel PCI strategy and also an increased risk of major adverse cardiac events with this strategy. The US National Cardiovascular Data Registry (28 936 STEMI patients) found increased mortality among 3087 patients with cardiogenic shock when primary multi-vessel PCI was used^[@EHQ410C25]^ and also a trend to increased mortality with this strategy among all STEMI patients (*Figure [2](#EHQ410F2){ref-type="fig"}*). Figure 2In-hospital mortality after multi-vessel vs. single-vessel percutaneous coronary intervention in STEMI (ST-elevation myocardial infarction) from the US National Cardiovascular Data Registry (adopted from Chen *et al*.^[@EHQ410C20]^).

Dambrink *et al*.^[@EHQ410C26]^ randomized 121 patients with multi-vessel disease after p-PCI for STEMI to (i) early fractional flow reserve (FFR)-guided staged PCI (performed 5--20 days after p-PCI, *n* = 80) vs. (ii) conservative therapy (*n* = 41). Forty per cent of the non-culprit lesions did not show haemodynamic significance (FFR \> 0.75) and subsequent PCI of at least one non-culprit lesion was performed only in 52% of patients in the invasive group. There was no difference in the left ventricular ejection fraction (EF) at 6 months (59 vs. 57%, *P* = 0.362) or in major adverse cardiovascular events (MACE) (21 vs. 22%, *P* = 0.929). The authors concluded that an invasive strategy towards non-culprit lesions does not lead to an increase in EF or a reduction in major adverse cardiovascular events (MACE). Furthermore, the functional stenosis severity of non-culprit lesions is frequently overestimated.

The recent meta-analysis of Sethi *et al*.^[@EHQ410C27]^ revealed nine non-randomized studies (with a total of 4530 patients treated by acute complete revascularization and 27 323 patients treated by the IRA PCI in the acute phase) and two small randomized studies. Major adverse cardiovascular events (OR = 0.95, 95% CI 0.47--1.90) and long-term mortality (OR = 1.10, 95% CI 0.76--1.59) were similar for both strategies.

Also one small single-centre retrospective study of Mohamad *et al*.^[@EHQ410C28]^ concluded that intervention of non-critical lesions did not seem to improve MACEs or all-cause mortality at 1 year of follow-up and might in fact have had a detrimental effect on outcomes.

A recently published secondary analysis of the APEX-acute myocardial infarction trial^[@EHQ410C12]^ found non-IRA PCI to be performed only in 9.9% of patients with STEMI and multi-vessel disease. Ninety-day death and death/congestive heart failure/shock were higher in this non-IRA group compared with the IRA-only PCI group (12.5 vs. 5.6%, *P* \<0.001 and 17.4 vs. 12.0%, *P* \< 0.020, respectively). After adjusting for patient and procedural characteristics as well as propensity for performing non-IRA PCI, this procedure remained independently associated with an increased hazard of 90-day mortality \[adjusted hazard ratio 2.44, 95% CI (1.55--3.83), *P* \<0.001\].

Intermediate approach: acute percutaneous coronary intervention of the infarct-related artery followed by staged percutaneous coronary intervention of secondary lesions {#s4}
========================================================================================================================================================================

The SWISSI II randomized trial^[@EHQ410C29]^ found elective (non-acute) PCI to be superior to medical therapy for patients with proven silent myocardial ischaemia after STEMI (*Figure [3](#EHQ410F3){ref-type="fig"}*; *Table [3](#EHQ410TB3){ref-type="table"}*). Table 3Infarct-related artery culprit lesions then staged secondary lesionsAdvantagesDisadvantagesOptimize potential for complete revascularizationEconomicsPCI of a stable stenosis might be intervened more safely at a later phase, after stabilizationMay treat asymptomatic lesionsComplications of treating secondary lesions early after index eventTiming uncertain Figure 3The SWISSI II randomized trial. Kaplan--Meier survivor function for cardiac death, non-fatal myocardial infarction, and symptom-driven revascularization. From Erne *et al*.^[@EHQ410C29]^ Permission for publication granted.

There are no published large randomized trials. We found only five small randomized studies,^[@EHQ410C17],[@EHQ410C26],[@EHQ410C30]--[@EHQ410C32]^ enrolling between 69 and 219 patients per study. These studies have significant limitations, the main being extremely low mortality (1.9% short-term and 3.8% long-term), which may reflect the high degree of pre-selection with high-risk STEMI patients being excluded. Four of these five randomized trials reported short-term mortality of STEMI patients between 0% (two studies) and 1.4%. Thus, their results may not be applicable to routine clinical practice. One small randomized study^[@EHQ410C33]^ compared multi-vessel PCI vs. culprit vessel only PCI in a small mixed group of patients including patients without previous acute myocardial infarction.

Advantages and disadvantages of multi-vessel percutaneous coronary intervention in ST-segment elevation myocardial infarction {#s5}
=============================================================================================================================

The summary of all above-mentioned trials and registries is in *Table [4](#EHQ410TB4){ref-type="table"}*. The reasons supporting multi-vessel PCI in STEMI patients and arguments against this strategy were summarized by Kornowski^[@EHQ410C34]^: Table 4The published studies comparing multi-vessel percutaneous coronary intervention in AMI vs. single (infarct-related artery)-vessel percutaneous coronary interventionFirst author (reference number)Number of patients in multi-vessel PCI groupNumber of patients in single-vessel PCI groupMain results*Randomized studies* Ijsselmuiden^[@EHQ410C31]^108111*No difference* in MACE rates at 1 month (14.4 vs. 9.3%), 1 year (32.4 vs. 26.9%), and 4.6 years (40.4 vs. 34.6%). Study conclusion: the decision of whether to perform culprit vessel or complete revascularization can be made on an individual basis. Politi^[@EHQ410C17]^13084Multi-vessel PCI *decreased* in-hospital death, repeat revascularisation, and rehospitalization (all *P* \< 0.05). Dambrink^[@EHQ410C26]^8041*No difference* in ejection fraction or in MACE. The stenosis severity of non-culprit lesions is frequently overestimated. Ochala^[@EHQ410C32]^92 (this study compared acute multi-vessel PCI vs. staged multi-vessel PCI)0 (no such group in this study)*No difference* in MACE. This study had too many exclusion criteria (STEMI mortality 0% in both groups!) to be relevant for clinical practice. Di Mario^[@EHQ410C30]^5217Multi-vessel PCI *increased* the duration of the procedure (69 vs. 53 min, *P* = 0.032) and the contrast load (341 vs. 242 mL, *P* = 0.025). Not significantly increased the in-hospital major adverse cardiac events (3.8 vs. 0%, *P* = 0.164).*Non-randomized registries* Cavender^[@EHQ410C25]^313425 802Multi-vessel PCI *increased* in-hospital mortality (7.9 vs. 5.1%, *P* \< 0.01), including patients with cardiogenic shock (36.5 vs. 27.8%; adjusted OR 1.54, 95% confidence interval 1.22--1.95). Hannan^[@EHQ410C22]^7972724After exclusion of cardiogenic shock patients, multi-vessel PCI *increased* in-hospital mortality (2.4 vs. 0.9%, *P* = 0.04). Staged multi-vessel PCI within 60 days *decreased* 1-year mortality (1.3 vs. 3.3%, *P* = 0.04). Toma^[@EHQ410C12]^2171984Multi-vessel PCI associated with an *increased* hazard of 90-day mortality \[adjusted HR 2.44, 95% CI (1.55--3.83), *P* \< 0.001\]. Kong^[@EHQ410C19]^6321350Multi-vessel PCI *decreased* in-hospital death (OR = 0.27, 95% confidence interval = 0.08--0.90, *P* = 0.03). Chen^[@EHQ410C20]^2391145*No difference* in mortality or combined death, myocardial infarction, coronary artery bypass graft, or target vessel revascularization. Corpus^[@EHQ410C21]^152354Multi-vessel PCI *increased* re-infarction (13.0 vs. 2.8%, *P* \< 0.001), revascularization (25 vs. 15%, *P* = 0.007), and MACEs (40 vs. 28%, *P* = 0.006) at 1 year (OR = 1.67, *P* = 0.01). Varani^[@EHQ410C18]^243159After exclusion of cardiogenic shock patients, multi-vessel PCI *decreased* 30-day mortality (2.8 vs. 6.3%, *P* = 0.023). Roe^[@EHQ410C24]^7979Multi-vessel PCI *increased* non-significantly the risk of death (25 vs. 16.4%, n.s.), re-infarction (8.8 vs. 1.6%, *P* \< 0.07) and significantly the risk of stroke (10.3 vs. 0%, *P* \< 0.01) at 6-month follow-up. Qarawani^[@EHQ410C15]^9525Multi-vessel PCI *decreased* major cardiac events (recurrent ischaemia, re-infarction, acute heart failure, and in-hospital mortality 16.7 vs. 52%, *P* = 0.0001). Rigattieri^[@EHQ410C16]^6446Multi-vessel PCI non-significantly *increased* in-hospital MACE (20.3 vs. 10.8%, *P* = 0.186); but *decreased* out of hospital MACE (9.3 vs. 23.9%, *P* = 0.037). Periprocedural myocardial infarction after the elective procedure occurred in 15.6% of patients. Khattab^[@EHQ410C23]^2845*No difference* in major adverse cardiac events at 1 year (24 vs. 28%, *P* = 0.73). Mohamad^[@EHQ410C28]^3429*No difference* (a trend for better outcomes in IRA PCI only).

*Reasons supporting multi-vessel PCI* include: *Plaque instability* may not be limited to the culprit lesion,^[@EHQ410C35]^ but may rather involve larger areas of the coronary tree (systemic endothelial dysfunction and higher platelet activity in acute coronary syndromes).*Complete coronary revascularization* is known to be associated with better long-term prognosis.*Patient preference*: patients may feel more comfortable when going home 'after complete repair'. Our experience repeatedly showed, that when we recommend medical therapy to patients with multi-vessel disease after successful p-PCI of the IRA, some patients seek second opinion in other cardiac centres and undergo a second PCI there.....Kornowski found more *reasons against acute multi-vessel PCI*: The acute phase of STEMI is a highly unstable condition (haemodynamic instability, heart failure, arrhythmias, resuscitation, and patient stress among others) and is thus certainly not an ideal situation to perform PCI of a stable stenosis, which might be intervened in probably more safely at a later phase, after stabilization.The acute phase of STEMI is an extremely prothrombotic and inflammatory milieu, which contributes to the potentially higher risk of additional PCI.Some degree of diffuse coronary spasm (either due to endothelial dysfunction or due to catecholamine use) is frequently present in the acute phase of STEMI, which may lead to possible overestimation of stenosis severity in non-infarct arteries.^[@EHQ410C36]^The decision to perform non-infarct artery PCI in the acute phase of STEMI is usually not supported by the objective evidence for myocardial ischaemia in regions supplied by this non-infarct artery. It is thus the classical 'occulo-stenotic' indication and not evidence-based indication for PCI.Multi-vessel PCI increases the contrast overload and further increases (already high) risk of contrast-induced nephropathy.Any potential PCI complications in the non-infarct artery may lead to catastrophic consequences (double myocardial jeopardy) including periprocedural death.The limited ability to discuss with patients and their families the relative risks and benefits of treating the non-infarct-related lesion vs. continued medical therapy or surgical options.

From literature review to real life: extreme variation of different clinical and angiographic scenarios! {#s6}
========================================================================================================

The main limitation of all the above-mentioned published papers is the simplification. Patients with multi-vessel disease are divided into two groups: those treated by acute or staged multi-vessel PCI and those not treated by this strategy. The every day real-life clinical practice brings much more different clinical scenarios. The decision to proceed with multi-vessel PCI is simple in the rare (∼1% of all p-PCIs) situation when two unstable (thrombus containing) IRA can be clearly demonstrated by the acute phase coronary angiography. This is the only situation, when there is almost no doubt about the PCI strategy (the only doubt is which artery should be dilated first). However, in the vast majority of p-PCIs, a single IRA can be easily recognized and treated.

There are ∼60 possible scenarios based on combinations of angiographic (number of diseased vessels, lesion severity, location and type, chronic total occlusions, thrombolysis in myocardial infarction flow, collaterals, wall motion in the supplied territory, etc.) and clinical (Killip class, immediate post-PCI haemodynamic situation, renal function, etc.) findings in individual patients. Clinical decision-making in this situation is thus really complex and should be always individualized. It is unlikely that any randomized clinical trial in the future can be able to fully address this complexity and thus, experienced, wise clinical judgement will probably remain the most important factor in this difficult situation.

Functional (exercise stress) testing along with the clinical picture (patients' symptoms) should be an important part of the decision-making algorithm. Patients who are asymptomatic and have negative functional tests and no evidence for silent ischaemia after their first STEMI should currently be treated conservatively.

The role of coronary bypass surgery (CABG) in patients with multi-vessel disease after STEMI was never investigated in a randomized study; however, it is a routine part of the clinical decision making. There is no uniform agreement on the CABG indications after STEMI treated by p-PCI. In most centres, once the culprit artery was treated by PCI, the other stenosed coronary arteries are either revascularized by staged PCI or are treated conservatively. However, in specific situations (e.g. triple-vessel disease with left main stenosis, anatomy not suitable for PCI, diabetes with triple-vessel disease, etc.), CABG should remain an important part of the treatment algorithm. Obviously, the indication for CABG should be supported by residual ischaemia (spontaneous or provoked) after STEMI.

What do the guidelines recommend? {#s7}
=================================

The European Society of Cardiology guidelines for PCI^[@EHQ410C37]^ state that in multi-vessel disease, p-PCI should be directed only at the infarct-related coronary artery. Decisions about PCI of non-culprit lesions should be done later and guided by objective evidence of residual ischaemia. Only in the setting of cardiogenic shock is there a consensus for attempting multi-vessel PCI in selected patients with multiple critical lesions.

A 2009 report on the appropriateness criteria for coronary revascularization written by the expert panel of the ACCF/SCAI/STS/AATS/AHA/ASNC^[@EHQ410C38]^ considers revascularization of a non-IRA during index hospitalization inappropriate in STEMI patients with successful treatment of the culprit artery by p-PCI or fibrinolysis when these patients are asymptomatic, without heart failure, have no evidence of recurrent or provocable ischaemia or did not have any unstable ventricular arrhythmias during the index hospitalization and have normal EF. On the other hand, STEMI or non-STEMI myocardial infarction patients after successful PCI of culprit artery with symptoms of recurrent myocardial ischaemia and/or high-risk findings on non-invasive stress testing performed after index hospitalization are suitable candidates for revascularization of additional coronary arteries.

Currently running/future trials {#s8}
===============================

Several studies are currently running trying to contribute to this question. One such study is led by D. Wood (<http://clinicaltrialsfeeds.org/clinical-trials/show/NCT01065103>), and another by O. Hlinomaz, and L. Groch (the PRAGUE-13 study). None of these is large enough to provide a definite answer. The authors are not currently aware about a larger ongoing study on this topic.

Conclusions {#s9}
===========

Multi-vessel disease in STEMI is not a single entity and thus the treatment approach should be individualized. However, the following general rules^[@EHQ410C39]^ can be proposed till future large randomized trials prove otherwise: Single-vessel acute PCI should be the default strategy (to treat only the IRA during the acute phase of STEMI).Acute multi-vessel PCI can be justified only in haemodynamically unstable patients with multiple truly *critical* (\>90%) lesions.Significant lesions of the non-culprit arteries should be treated either medically or by staged revascularization procedures---both options are currently acceptable.
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